Linked Life Data

19995374

Source:http://linkedlifedata.com/resource/pubmed/id/19995374

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2010-5-21
pubmed:abstractText
PURPOSE: Introduction of rituximab has largely improved the prognosis of patients with diffuse large B-cell lymphoma(DLBCL). Such change in therapeutic outcome necessitates the identification of additional prognostic factors to conventional indexes that have been validated for CHOP without rituximab. Indoleamine 2,3-dioxygenase (IDO) exerts intense immunomodulatory effects because of enzymatic activities that catalyze the breakdown of the essential amino acid L-tryptophan. The activity of IDO can be estimated by measuring the serum concentration of L-kynurenine. Here, we investigated the role of L-kynurenine as a prognostic marker in R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) therapy. Experimental design: Data from 73 consecutive patients treated with eight cycles of R-CHOP or R-THP (tetrahydropyranyl adriamycin)-COP between December 2002 and March 2007 were analyzed. L-kynurenine concentrations in serum samples obtained at admission were measured by high-performance liquid chromatography. Results: The median serum L-kynurenine level was 1.575 microm (range 0.537-9.588). The complete response (CR) rates of patients with L-kynurenine <1.5 and > or =1.5 microm were 83% and 61%, respectively (P < 0.05). The three-yr overall survival (OS) rates for patients with L-kynurenine <1.5 and > or =1.5 microm were 89% and 58%, respectively (P < 0.005). In addition, higher age, poor performance status, elevated serum lactate dehydrogenase, and unfavorable as well as revised International Prognosis Index were significantly worse factors for CR rate and OS. Multivariate analyses revealed only L-kynurenine as an independent prognostic factor for OS. Conclusions: Serum L-kynurenine might be a novel prognostic factor to determine the treatment outcome of DLBCL with the R-CHOP regimen.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1600-0609
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
84
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
304-9
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:19995374-Adult, pubmed-meshheading:19995374-Aged, pubmed-meshheading:19995374-Antibodies, Monoclonal, pubmed-meshheading:19995374-Antibodies, Monoclonal, Murine-Derived, pubmed-meshheading:19995374-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:19995374-Cyclophosphamide, pubmed-meshheading:19995374-Disease-Free Survival, pubmed-meshheading:19995374-Doxorubicin, pubmed-meshheading:19995374-Female, pubmed-meshheading:19995374-Humans, pubmed-meshheading:19995374-Kynurenine, pubmed-meshheading:19995374-Lymphoma, Large B-Cell, Diffuse, pubmed-meshheading:19995374-Male, pubmed-meshheading:19995374-Middle Aged, pubmed-meshheading:19995374-Prednisolone, pubmed-meshheading:19995374-Remission Induction, pubmed-meshheading:19995374-Survival Rate, pubmed-meshheading:19995374-Vincristine
pubmed:year
2010
pubmed:articleTitle
Serum concentration of L-kynurenine predicts the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP.
pubmed:affiliation
First Department of Internal Medicine, Gifu University Graduate School of Medicine, Gifu, Japan.
pubmed:publicationType
Journal Article, Clinical Trial